Hereditary Cancer Panel denied due to quantity / dose limits by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for hereditary cancer panel are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare Applies Quantity Limits to Hereditary Cancer Panel Testing

Although hereditary cancer panels are one-time or infrequent tests rather than a recurring prescription, UnitedHealthcare may apply a quantity or frequency limit — for example, limiting coverage to one hereditary panel per lifetime or requiring that a prior single-gene test be performed before a broader panel is authorized. A quantity-limits denial in this context usually means that UHC's records show a prior panel was already covered for this patient, or that the breadth of the panel requested exceeds what UHC's policy defines as a single covered test event.

## Why This Denial Is Appealable

Quantity or frequency limits on genetic testing are contestable when the clinical circumstances have materially changed since any prior test, when a prior test was performed with technology that did not cover the genes now clinically indicated, or when a new personal diagnosis (rather than family history alone) creates a distinct and independent medical indication. The key argument is that this is not a duplicative service but a clinically distinct, medically necessary test event.

## Your Federal Appeal Rights

• Internal appeal: File under ERISA §503 (employer plans) or applicable state insurance law. Challenge whether UHC's quantity limit as applied to this patient's current clinical situation constitutes a clinically reasonable coverage restriction.
• External review: ACA §2719 entitles you to independent external review after internal remedies are exhausted. The standard window is approximately four months from the final internal denial. Request expedited review if clinical timing is urgent.

## Concrete Appeal Steps and Timeline

1. Obtain documentation of any prior genetic testing — what genes were included, the technology used, and the date performed. 2. Identify what has clinically changed since the prior test (new diagnosis, new family history information, updated professional guidelines recommending expanded panel scope, or technological limitations of the original test). 3. Have the ordering clinician write a letter explaining the clinical distinction between prior and current testing. 4. Submit a Level 1 internal appeal with this clinical rationale and supporting records. 5. If denied, escalate to external IRO review.

## Documentation to Gather

• Prior test records: The original genetic test report — including the laboratory, panel name, gene list covered, and date — to establish what was and was not tested previously.
• Gap analysis: A statement from the ordering clinician or genetic counselor describing which genes now clinically indicated were not included in prior testing, or why the prior result is insufficient to guide current management.
• New clinical developments: Any new personal diagnosis, updated pathology, or significant family history expansion that postdates the prior test.
• Current clinical management rationale: How the additional test results will change surveillance, surgical planning, or treatment decisions.
• Updated professional guidelines: A reference to the relevant guideline organization's current recommendations (e.g., NCCN, ACMG) indicating that broader panel testing is now the standard of care for this indication — without citing specific numbers from the guideline.

## Criteria-Mapping Structure

Request UHC's published quantity-limit policy for hereditary cancer testing. Map each element of the limit to your clinical facts, focusing on the distinction between the prior test and the current request. The goal is to establish that these are not the same service repeated, but two clinically distinct testing events separated by a meaningful change in the patient's clinical picture.